ELTX
Elicio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.42
−3.40%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$63.47M
MomentumView details →
1D Return
−3.40%
YTD Return
−69.66%
RSI (14)
27.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$63.47M
RSI (14)
27.6
MomentumView details →
1D Return
−3.40%
YTD Return
−69.66%
SummaryUpdated Jun 1, 2026
Elicio Therapeutics, Inc. (NASDAQ:ELTX) is a clinical-stage biotechnology company founded and headquartered in Boston, Massachusetts. The company went public in February 2021 and focuses on developing novel immunotherapies for cancer treatment and other diseases. As a clinical-stage biotech firm, Elicio operates without generating revenue from product sales, instead relying on research and development activities to advance its pipeline of experimental treatments through various phases of clinical trials.
Similar companies
Latest newsMore news →
Elicio Therapeutics priced a registered direct offering of 4,380,313 shares of common stock for gross proceeds of approximately $15 million.65d agoElicio Therapeutics reported clinical observations for its ELI-002 7P cancer drug, indicating durable responses.79d agoElicio Therapeutics shares fell about 73% in early trading on Monday after its pancreatic cancer therapy failed a mid-stage study.81d ago